PE20140964A1 - Antidotos anticoagulantes - Google Patents

Antidotos anticoagulantes

Info

Publication number
PE20140964A1
PE20140964A1 PE2013002078A PE2013002078A PE20140964A1 PE 20140964 A1 PE20140964 A1 PE 20140964A1 PE 2013002078 A PE2013002078 A PE 2013002078A PE 2013002078 A PE2013002078 A PE 2013002078A PE 20140964 A1 PE20140964 A1 PE 20140964A1
Authority
PE
Peru
Prior art keywords
seq
group
refers
cdr3
variable domain
Prior art date
Application number
PE2013002078A
Other languages
English (en)
Spanish (es)
Inventor
Ryn Joanne Van
Keith Canada
Robert Copenhaver
Norbert Hauel
Tobias Litzenburger
Christopher Ronald Sarko
Sanjaya Singh
Alisa K Waterman
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140964(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20140964A1 publication Critical patent/PE20140964A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2013002078A 2011-03-30 2012-03-27 Antidotos anticoagulantes PE20140964A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161469207P 2011-03-30 2011-03-30

Publications (1)

Publication Number Publication Date
PE20140964A1 true PE20140964A1 (es) 2014-08-17

Family

ID=45876804

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002078A PE20140964A1 (es) 2011-03-30 2012-03-27 Antidotos anticoagulantes

Country Status (23)

Country Link
US (2) US8821871B2 (cg-RX-API-DMAC7.html)
EP (1) EP2691156A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014515740A (cg-RX-API-DMAC7.html)
KR (1) KR20140009437A (cg-RX-API-DMAC7.html)
CN (1) CN103476459A (cg-RX-API-DMAC7.html)
AP (1) AP2013007046A0 (cg-RX-API-DMAC7.html)
AR (1) AR085758A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013025031A2 (cg-RX-API-DMAC7.html)
CA (1) CA2827787A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013002551A1 (cg-RX-API-DMAC7.html)
CO (1) CO6771448A2 (cg-RX-API-DMAC7.html)
EA (1) EA201301090A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012997A (cg-RX-API-DMAC7.html)
IL (1) IL227653A0 (cg-RX-API-DMAC7.html)
MA (1) MA34978B1 (cg-RX-API-DMAC7.html)
MX (1) MX2013011092A (cg-RX-API-DMAC7.html)
PE (1) PE20140964A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013501924A1 (cg-RX-API-DMAC7.html)
SG (1) SG193552A1 (cg-RX-API-DMAC7.html)
TN (1) TN2013000388A1 (cg-RX-API-DMAC7.html)
TW (1) TW201302796A (cg-RX-API-DMAC7.html)
UY (1) UY33994A (cg-RX-API-DMAC7.html)
WO (1) WO2012130834A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
AR089020A1 (es) 2011-11-29 2014-07-23 Perosphere Inc Agentes de reversion anticoagulante
CA2914369C (en) 2013-06-06 2023-02-14 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
EP3027624B1 (en) * 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
WO2015059159A1 (en) * 2013-10-25 2015-04-30 Boehringer Ingelheim International Gmbh Anticoagulant antidotes
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
EP3784281A4 (en) * 2018-04-27 2022-02-16 Seattle Children's Hospital d/b/a Seattle Children's Research Institute IN VIVO GENE THERAPY USING ADMINISTRATION OF A LENTIVIRAL GENE CONSTRUCT

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
RU2128709C1 (ru) 1992-01-23 1999-04-10 Мерк Патент Гмбх Способ получения димерного одноцепочечного слитого белка (варианты)
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
FI955798L (fi) 1993-06-03 1996-02-01 Therapeutic Antibodies Inc Terapeuttiset vasta-ainefrangmentit
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP2316951A1 (en) 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
EP3824902A1 (en) 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
JP2013502449A (ja) 2009-08-24 2013-01-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシレート過剰投与による活性炭の緊急処置
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
KR20140009437A (ko) 2014-01-22
NZ613543A (en) 2015-07-31
CL2013002551A1 (es) 2014-02-14
IL227653A0 (en) 2013-09-30
EA201301090A1 (ru) 2014-05-30
BR112013025031A2 (pt) 2017-08-01
CN103476459A (zh) 2013-12-25
TW201302796A (zh) 2013-01-16
AR085758A1 (es) 2013-10-23
US20120276123A1 (en) 2012-11-01
US8821871B2 (en) 2014-09-02
UY33994A (es) 2012-09-28
TN2013000388A1 (en) 2015-01-20
US20140377265A1 (en) 2014-12-25
JP2014515740A (ja) 2014-07-03
MA34978B1 (fr) 2014-03-01
CO6771448A2 (es) 2013-10-15
SG193552A1 (en) 2013-11-29
AP2013007046A0 (en) 2013-08-31
MX2013011092A (es) 2013-12-06
CA2827787A1 (en) 2012-10-04
ECSP13012997A (es) 2013-12-31
PH12013501924A1 (en) 2017-10-25
WO2012130834A1 (en) 2012-10-04
EP2691156A1 (en) 2014-02-05

Similar Documents

Publication Publication Date Title
PE20140964A1 (es) Antidotos anticoagulantes
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20131209A1 (es) Anticuerpos anti-fap
PE20140814A1 (es) Anticuerpos contra la angiopoyetina 2 humana
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20190208A1 (es) Anticuerpos que reconocen tau
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
TN2012000366A1 (en) Anticoagulant antidotes
MX373245B (es) Anticuerpos cd3 humanizados o quiméricos.
AR084315A1 (es) Anticuerpos anti-notch1
PE20150002A1 (es) Anticuerpos anti-fcrn
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
GT201400045A (es) Anticuerpo anti-abtcr
CY1116488T1 (el) Αντισωματα anti-προπερδινης
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
AR100978A1 (es) LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EA201400447A1 (ru) АНТИТЕЛА К CD1d
PE20141547A1 (es) Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
ES2722824T3 (es) Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal